PREGUNTA 1: Alternativa  d)

Referencia:
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferranini E, NauckM et al 2012. Management of Hyperglycemia in Type 2 Diabetes: A Pacient- Centered Aproach. Position Estatement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (6): 1364-1379.
Diabetologia 2012, 55 (6): 1577-1596.

PREGUNTA 2: Alternativa  e)

Referencias:
Power M and Pratley R. 2011. Alternative and Complementary Treatments for the Metabolic Syndrome. Curr Diab Rep 11: 173-178.
Lugnier C. 2011. PDE inhibitors: a new approach to treat Metabolic Syndrome. Curr Pharmacol Rep 11: 698-706.

PREGUNTA 3: Alternativa  d)

Referencia:
Standards of Medical Care in Diabetes. Position Statement. 2012. Diabetes Care 35 (S1): S11-S63.

PREGUNTA 4: Alternativa  c)

Referencia:
DeFronzo RA. 2010. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53 (7): 1270-1287.

PREGUNTA 5: Alternativa  b)

Referencia:
Reimondo G, Pia A, Bovio S, Allasino B, Daffara F, Paccotti P, Borretta G, Angeli A, Terzolo M. 2008. Laboratory differentiation of Cushing´s syndrome. Clin Chim Acta 388 (1-2): 5-14.

PREGUNTA 6: Alternativa  c)

Referencia:
Sugandhan S, Khandpur S, Sharma VK. 2007. Familial chylomicronemia syndrome. Pediatr Dermatol 24 (3): 323-325.

PREGUNTA 7: Alternativa  a)

Referencia:
Hare MJ, Shaw JE, Zimmet PZ. 2012. Current controversies in the use of haemoglobin A1c. J Intern Med 271 (3): 227-36.

PREGUNTA 8: Alternativa  c)

Referencia:
Bhargava P, Lee CH. 2012. Role and function of macrophages in the metabolic syndrome. Biochem J 442 (2): 253-62.